Pacylex

Pacylex Presents Evidence Supporting Advancement of PCLX-001 for Treatment of AML at AACR 2022

New data on PCLX-001 being presented at AACR showing the potential for N-myristoylation inhibition to treat for AML with in vitro and animal model data: PCLX-001 dramatically reduces AML stem cells in the bone marrow.

Read More

Recent News

Pacylex

Pacylex Presents Evidence Supporting Advancement of PCLX-001 for Treatment of AML at AACR 2022

Read More

Pacylex

First Clinical Experience with an N-myristoyltransferase (NMT) inhibitor in a patient published

Read More

Pacylex

Pacylex Presented Initial Clinical Experience with PCLX-001 in Patients at ASH 2021

Read More
Follow Pacylex